These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25712992)

  • 1. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.
    Oldenburg J
    Blood; 2015 Mar; 125(13):2038-44. PubMed ID: 25712992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of prophylactic treatment in patients with hemophilia.
    López Fernández MF
    Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S22-S24. PubMed ID: 31157677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
    Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
    J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in hemophilia and the role of current and emerging prophylaxis.
    Acharya SS
    Am J Manag Care; 2016 Apr; 22(5 Suppl):s116-25. PubMed ID: 27266808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease.
    Hilgartner MW; Makipernaa A; Dimichele DM
    Haemophilia; 2003 May; 9(3):261-8. PubMed ID: 12694515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Joint Bleeding Tendencies in Adult Patients With Hemophilia: It's Not All Pharmacokinetics.
    Zhou JY; Barnes RFW; Foster G; Iorio A; Cramer TJ; von Drygalski A
    Clin Appl Thromb Hemost; 2019; 25():1076029619862052. PubMed ID: 31298044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis with factor concentrates in preventing hemophilic arthropathy.
    Petrini P; Lindvall N; Egberg N; Blombäck M
    Am J Pediatr Hematol Oncol; 1991; 13(3):280-7. PubMed ID: 1793153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis for severe hemophilia: experience from Europe and the United States.
    van den Berg HM; Fischer K
    Semin Thromb Hemost; 2003 Feb; 29(1):49-54. PubMed ID: 12640565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia and prophylaxis.
    Ljung R
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging evidence for subclinical joint bleeding in a Dutch population of people with severe hemophilia on prophylaxis.
    van Leeuwen FHP; van Bergen EDP; Timmer MA; van Vulpen LFD; Schutgens REG; de Jong PA; Fischer K; Foppen W
    J Thromb Haemost; 2023 May; 21(5):1156-1163. PubMed ID: 36758725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Articular Bleeding in Hemophilia.
    Rodriguez-Merchan EC
    Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):21-24. PubMed ID: 28049407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy].
    Meunier S; Trossaërt M; Berger C; Borel-Derlon A; Dirat G; Donadel-Claeyssens S; Assolant AD; Guérois C; Lutz P; Rafowicz A; Rothschild C; Chambost H;
    Arch Pediatr; 2009 Dec; 16(12):1571-8. PubMed ID: 19960603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome.
    Fischer K; Van Der Bom JG; Prejs R; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; Van Den Berg HM
    Haemophilia; 2001 Nov; 7(6):544-50. PubMed ID: 11851751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project.
    Manco-Johnson MJ; Soucie JM; Gill JC;
    Blood; 2017 Apr; 129(17):2368-2374. PubMed ID: 28183693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.
    Kumar R; Dunn A; Carcao M
    Semin Thromb Hemost; 2016 Feb; 42(1):18-29. PubMed ID: 26771678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.